The planned measures by the member companies of the European Federation of Pharmaceutical Industries and Associations (EFPIA), which include 20 of the world’s largest pharmaceutical companies, are intended to “significantly increase” the availability of innovative medicines in EU countries. In addition, patients’ waiting time for new medicines is to be reduced by several months, according to the current EFPIA statement.
Continue reading now
Get 30 days of free access to the Decision Brief to read these and more quality news every day.
Are you already a guest at the Europe.Table? Log in now